Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation
Ischemic heart disease and stroke are major causes of death and morbidity worldwide. Coronary and cerebrovascular events are a consequence of thrombus formation caused by atherosclerotic plaque rupture or embolism, both of which result from platelet activation and aggregation and thrombin-mediated fibrin generation via the coagulation cascade [1]. In addition, thrombin is also one of the most effective platelet activators [2]. We focused on a novel thrombus formation mechanism called thrombin-mediated platelet stimulation and established thrombin-induced platelet aggregation [3].
Source: Thrombosis Research - Category: Hematology Authors: Keisuke Tsuda, Tatsunori Natori, Mie Shimizu, Yoko Ishigaku, Kiyotaka Oi, Shinsuke Narumi, Asami Kamada, Makiko Yoshida, Kazumasa Oura, Tetsuya Maeda, Yasuo Terayama Tags: Letter to the Editors-in-Chief Source Type: research
More News: Atrial Fibrillation | Cardiology | Heart | Heart Disease | Hematology | Ischemic Stroke | Pradaxa | Stroke | Thrombosis